This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Quipt Home Medical Corp. (QIPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 66.67% and 3.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quipt Home Medical Corp. (QIPT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 100% Upside in Quipt Home Medical Corp. (QIPT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 100% upside potential for Quipt Home Medical Corp. (QIPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Quipt Home Medical Corp. (QIPT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of -250% and 1.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Asensus Surgical (ASXC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of -28.57% and 18.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Soars 33.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Envista (NVST) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of -7.32% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Quipt Home Medical Corp. (QIPT) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quipt Home Medical Corp. (QIPT) Beats Q4 Earnings Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 25% and 1.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Quipt Home Medical Corp. (QIPT) Reports Break-Even Earnings for Q3
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of -100% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -55.56% and 42.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 9.43% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 16.67% and 2.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Quanterix Corporation (QTRX): Can Its 5.1% Jump Turn into More Strength?
by Zacks Equity Research
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Quipt Home Medical Corp. (QIPT) Tops Q2 Earnings Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 366.67% and 4.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Quipt (QIPT) Ahead of Earnings?
by Zacks Equity Research
Quipt (QIPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -100% and 4.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Quipt Home Medical Corp. (QIPT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clover Health (CLOV) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.
Insulet (PODD) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 73.91% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Quipt (QIPT) Ahead of Earnings?
by Zacks Equity Research
Quipt (QIPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
QIPT vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
QIPT vs. BSX: Which Stock Is the Better Value Option?